Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 

33 protocols found



Protocol No. Title Status
UW18001 A Multicenter, Open Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated with Cancer Open
NCI9782 A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors Open
UW16107 A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors Open
UW17055 A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors Open
UW15054 A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies Open
UW16140 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies Open
AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors Open
UW17031 A Phase I Study of PCUR-101 in Combination with Androgen Suppression Therapy in the Treatment of Patients with Metastatic Castrate-Resistant Prostate Cancer Open
UW16116 A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Rα)) alone and in combination with PDR001 in Adults with Metastatic Cancers Open
UW14083 A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Simultaneous Integrated Boost and Urethral-Sparing IMRT Planning Open
ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) Open
NRGGU003 A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) versus Conventional Post Prostatectomy Radiation Therapy (COPORT) Open
UW17120 An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA) Open
UW16137 An Open-Label, Dose-Finding And Proof Of Concept Study Of The Pd-L1 Probody Therapeutic, Cx-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Anti-Pd-1/Pd-L1 Inhibitor Naïve Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas Open
RTOG0924 Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial Open
UW17038 Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial:(CANVAS Trial) Open
A171603 Feasibility of an Electronic Geriatric Assessment for Older Adults with Cancer Open
UW16029 Feasibility of delivering electronic health record (EHR)-based survivorship care plans and planning to cancer survivors in a community oncology practice Open (affiliates only)
UW15106 Genomic analysis of long-term survivors with metastatic cancer Open
EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
APEC1621B NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations Open
APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MapK Pathway Mutations Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Open
UW16062 PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer Open
UW16059 Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire Open
ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Open
UW17009 Pilot neoadjuvant trial of chemohormonal therapy followed by prostatectomy in patients with high risk and oligometastatic prostate cancer Open
UW15014 Pilot trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients with Castration-Resistant, Metastatic Prostate Cancer Open
UW17130 Seminal Samples for Molecular Analysis Open
UW15052 Validation of Imaging-Based Biomarkers of Treatment Response in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide Open